Clinical trialNCT00002642CompletedPhase 2Interventional

SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer

SponsorSWOG Cancer Research NetworkEnrollment116Lung Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to kill tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy using cisplatin and etoposide, radiation therapy, and surgery, with adjuvant therapy using cisplatin and etoposide, in treating patients who have stage III non-small cell lung cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Claude Deschamps, MD
Mayo Clinic
Study Chair
clinicaltrials.gov ↗
David H. Johnson, MD
Vanderbilt-Ingram Cancer Center
Study ChairKOL profile →
clinicaltrials.gov ↗
Lawrence N. Shulman, MD
Dana-Farber Cancer Institute
Study Chair
clinicaltrials.gov ↗
Ronald L. Burkes, MD, FRCPC
Mount Sinai Hospital, Canada
Study Chair
clinicaltrials.gov ↗
Valerie W. Rusch, MD, FACS
Memorial Sloan Kettering Cancer Center
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Vanderbilt Cancer Center
Nashville, Tennessee, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cisplatin →Etoposide →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Apr 1995
Primary completion: 31 Jan 2001
Completion: 31 Jul 2004
Last update posted: 8 Oct 2012
Registered enrollment: 116
Registry id: NCT00002642

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.